$Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas$

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas

Stefano Volpetti, Francesco Zaja, Renato FaninDivision of Hematology and Cellular Therapies Unit “Carlo Melzi”, Department of Experimental and Clinical Sciences, University Hospital “Santa Maria della Misericordia”, Udine, ItalyAbstract: Treatment of patients...

Full description

Bibliographic Details
Main Authors:	Volpetti S, Zaja F, Fanin R
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-05-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/pixantrone-for-the-treatment-of-adult-patients-with-relapsed-or-refrac-a17058

Similar Items

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
by: Jezeršek Novaković B, et al.
Published: (2021-03-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

Third line Treatment in Relapsed/Refractory Hodgkin's Lymphoma and Aggressive non-Hodgkin Lymphoma after 2nd line ESHAP or GEMOX
by: Hamdy Zawam, et al.
Published: (2018-06-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

New agents in relapsed/refractory Hodgkin's lymphoma
by: Irene Biasoli, et al.

CLINICAL CHARACTERISTICS AND TREATMENT RESULTS OF PEDIATRIC RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS
by: T. T. Valiev
Published: (2018-07-01)

Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients
by: Elisa Lucchini, et al.
Published: (2021-06-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
by: Siddiqi T, et al.
Published: (2014-02-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01)

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas
by: EA Demina
Published: (2015-10-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018-05-01)

Bendamustine in the Treatment of Relapsed/Refractory Hodgkin’s Lymphoma: Literature Review and Clinical Experience
by: SS Shklyaev, et al.
Published: (2019-03-01)

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012-05-01)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
by: Novakovic Barbara Jezersek
Published: (2015-12-01)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
by: Simon Hallam
Published: (2018-08-01)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
by: Roberta Fedele, et al.
Published: (2015-01-01)

Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
by: Chao MP
Published: (2013-08-01)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
by: Gutierrez A, et al.
Published: (2014-11-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

The Use of Brentuximab Vedotin in Relapsed/Refractory Hodgkin’s Lymphoma in the Kransnodar Region
by: OD Serdyuk, et al.
Published: (2018-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab Vedotin
by: Michelle Furtado, et al.
Published: (2012-01-01)

Genomic Instability: The Driving Force behind Refractory/Relapsing Hodgkin’s Lymphoma
by: Sabine Mai, et al.
Published: (2013-06-01)

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
by: Patrick B. Johnston, et al.
Published: (2018-05-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
by: Davids, Matthew S., et al.
Published: (2017)

Epidemiology, prognosis and treatment of aggressive non-Hodgkin lymphomas
by: Sieniawski, Michal Konrad
Published: (2017)

Hodgkin Lymphoma : Studies of Advanced Stages, Relapses and the Relation to Non-Hodgkin Lymphomas
by: Amini, Rose-Marie
Published: (2002)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Mohammadali Mashhadi, et al.
Published: (2011-09-01)

IEV (Ifosfamide, Epirubicin, VP16) Regimen as Salvage Therapy for Early Relapsed/Refractory non-Hodgkin/Hodgkin Lymphoma
by: Behrooz Najafi, et al.
Published: (2011-10-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

Durability Results of Treatment with Brentuximab Vedotin in Combination with Nivolumab in Patient with Relapsed or Refractory Hodgkin Lymphoma
by: Minhas, Ahmed, et al.
Published: (2020)

Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma
by: Eva Fernández Cañabate, et al.
Published: (2018-01-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

Nursing management of patients with relapsed or refractory classical Hodgkin's lymphoma treated with sintilimab
by: KUANG Meiling
Published: (2021-01-01)